TB Reactivation on Anti-TNF — SCE Infectious Diseases MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Consider immune-related false negativity and investigate active and latent TB
A negative IGRA does not override substantial epidemiological and radiographic risk. The infliximab SmPC warns that false-negative TB tests can occur in severe illness or immunocompromise and requires evaluation for active and latent TB before treatment. Active disease must be excluded and the need for preventive treatment considered with specialist input before TNF blockade.
Reference: Remicade Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/3831/smpc